Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Interest & Investment Income of $8.2 million for Q1 2026, down 12.03% year-over-year from $9.4 million in Q1 2025, and down 12.86% quarter-over-quarter from $9.5 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Interest & Investment Income data on file, last reported at $8.2 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $8.2 million, down 12.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.2 million (down 24.02% YoY), and the FY2025 annual result was $37.4 million, down 19.91% from the prior year.
- Interest & Investment Income declined to $8.2 million in Q1 2026 per MDGL's latest filing, from $9.5 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $14.2 million in Q2 2024 and troughed at $69000.0 in Q1 2022.
- A 5-year average of $6.7 million and a median of $8.2 million in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 56.88% in 2022, then soared 5372.46% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $1.1 million in 2022, then jumped by 732.06% to $9.0 million in 2023, then advanced by 23.75% to $11.1 million in 2024, then dropped by 14.62% to $9.5 million in 2025, then decreased by 12.86% to $8.2 million in 2026.
- Business Quant data shows MDGL's Interest & Investment Income at $8.2 million in Q1 2026, $9.5 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | 8.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.24 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | 10.31 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 9.37 Mn |
| Dec 31, 2024 | 11.08 Mn |
| Sep 30, 2024 | 13.02 Mn |
| Jun 30, 2024 | 14.22 Mn |
| Mar 31, 2024 | 8.33 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.55 Mn |
| Mar 31, 2023 | 3.78 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 717,000.00 |
| Jun 30, 2022 | 323,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Dec 31, 2021 | 52,000.00 |
| Sep 30, 2021 | 60,000.00 |
| Jun 30, 2021 | 91,000.00 |